Vivos (RDGL) Debt-to-Asset : 0.00 (As of Mar. 2025)

View and export this data going back to . Start your Free Trial

What is Vivos Debt-to-Asset?

Vivos's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.00 Mil. Vivos's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $0.00 Mil. Vivos's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2025 was $3.30 Mil. Vivos's debt to asset for the quarter that ended in Mar. 2025 was 0.00.

Vivos Debt-to-Asset Historical Data

The historical data trend for Vivos's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivos Debt-to-Asset Chart

Vivos Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.37

Vivos Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Debt-to-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Vivos's Debt-to-Asset

For the Medical Devices subindustry, Vivos's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vivos's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vivos's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Vivos's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Vivos Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Vivos's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	2.233
	=	0.00

Vivos's Debt-to-Asset for the quarter that ended in Mar. 2025 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	3.302
	=	0.00

Vivos (OTCPK:RDGL) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Vivos Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Vivos's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivos Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vivos Inc (OTCPK:RDGL) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

1030 N Center Parkway, Kennewick, WA, USA, 99352

Website

https://www.radiogel.com

Vivos Inc is a radiation oncology medical device company. It is engaged in the development of RadioGel which is a brachytherapy device comprising highly insoluble particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors. IsoPet is another product of the company used for the treatment of solid tumors in animals. The company derives revenue through sales of its products.

Executives

Michael K Korenko	officer: INTERIM CEO AND PRESIDENT	6208 W OKANOGAN AVE, KENNEWICK WA 99336
Michael H Pollack	officer: Interim CFO	114 WEST 47TH STREET, 19TH FLOOR, NEW YORK NY 10036
Memorial Institute Battelle	10 percent owner	505 KING AVENUE, COLUMBUS OH 43201
Kenin M. Spivak	director	9663 SANTA MONICA BLVD., #1048, BEVERLY HILLS CA 90210
Thomas J Clement	director	12445 110TH LANE NE, APT. Q-302, KIRKLAND WA 98034
Leonard Bruce Jolliff	officer: Chief Financial Officer	206 N 41ST ST., UNIT 1, YAKIMA WA 98901
Cadwell Family Irrevocable Trust	10 percent owner	909 NORTH KELLOGG STREET, KENNEWICK WA 99336
James C Katzaroff	director, 10 percent owner, officer: CEO	719 JADWIN AVE., RICHLAND WA 99352
Bruce Wayne Ratchford	director, 10 percent owner	6208 W. OKANOGAN AVE., KENNEWICK WA 99336
Carlton M Cadwell	director, 10 percent owner	6208 W OKANOGAN AVE, KENNEWICK WA 99336